Validation of the Italian version of the abbreviated expanded prostate Cancer index composite (EPIC-26) in men with prostate Cancer.
Decision-making
Epic-26
Prostate cancer
Quality of life
Validation
Journal
Health and quality of life outcomes
ISSN: 1477-7525
Titre abrégé: Health Qual Life Outcomes
Pays: England
ID NLM: 101153626
Informations de publication
Date de publication:
29 Aug 2019
29 Aug 2019
Historique:
received:
03
12
2018
accepted:
16
08
2019
entrez:
30
8
2019
pubmed:
30
8
2019
medline:
12
11
2019
Statut:
epublish
Résumé
This study aims to validate and evaluate the psychometric properties and reliability of the Italian version of the Expanded Prostate Cancer Index Composite - Short Form (EPIC-26), a measure of quality of life (QoL) for prostate cancer patients. Two hundred and eighty-four prostate cancer patients completed the Italian version of the EPIC-26 questionnaire at 45 days (T1) and 3 months (T2) after robot-assisted radical prostatectomy (RARP). Psychometric properties were evaluated using structural equation modeling: the goodness of fit of the correlated five-factor model (CFFM) for the EPIC-26 was assessed using the confirmatory factor analysis (CFA), while longitudinal invariance was conducted to assess the ability of the EPIC-26 to measure QoL construct over time. Test-retest reliability was assessed as well by considering intraclass correlations. At T1, the CFFM model displayed a good fit to data. Similarly, the model showed an adequate fit also at T2. Results of the reliability analysis attested the acceptable internal consistency and test-retest reliability of each dimension: all Cronbach's alphas could be classified as acceptable (i.e., above .65) except for low Cronbach's alpha for hormonal dysfunction at T1 (i.e., .638) and urinary irritation at both waves. (i.e., respectively .585 and .518). Finally, psychometric properties were invariant over time and each of the five dimensions of QoL displayed from moderate (all ICCs above .500) to good test-retest reliability (i.e. ICC for urinary incontinence = .764). Results of the CFA and the measurement invariance analysis demonstrated the validity of the Italian version of the EPIC-26 to assess QoL in prostate cancer patients. Its reliability and good psychometric qualities are well-supported, thus providing a valid tool to assess health-related quality of life and its change over time in prostate cancer patients.
Sections du résumé
BACKGROUND
BACKGROUND
This study aims to validate and evaluate the psychometric properties and reliability of the Italian version of the Expanded Prostate Cancer Index Composite - Short Form (EPIC-26), a measure of quality of life (QoL) for prostate cancer patients.
METHODS
METHODS
Two hundred and eighty-four prostate cancer patients completed the Italian version of the EPIC-26 questionnaire at 45 days (T1) and 3 months (T2) after robot-assisted radical prostatectomy (RARP). Psychometric properties were evaluated using structural equation modeling: the goodness of fit of the correlated five-factor model (CFFM) for the EPIC-26 was assessed using the confirmatory factor analysis (CFA), while longitudinal invariance was conducted to assess the ability of the EPIC-26 to measure QoL construct over time. Test-retest reliability was assessed as well by considering intraclass correlations.
RESULTS
RESULTS
At T1, the CFFM model displayed a good fit to data. Similarly, the model showed an adequate fit also at T2. Results of the reliability analysis attested the acceptable internal consistency and test-retest reliability of each dimension: all Cronbach's alphas could be classified as acceptable (i.e., above .65) except for low Cronbach's alpha for hormonal dysfunction at T1 (i.e., .638) and urinary irritation at both waves. (i.e., respectively .585 and .518). Finally, psychometric properties were invariant over time and each of the five dimensions of QoL displayed from moderate (all ICCs above .500) to good test-retest reliability (i.e. ICC for urinary incontinence = .764).
CONCLUSIONS
CONCLUSIONS
Results of the CFA and the measurement invariance analysis demonstrated the validity of the Italian version of the EPIC-26 to assess QoL in prostate cancer patients. Its reliability and good psychometric qualities are well-supported, thus providing a valid tool to assess health-related quality of life and its change over time in prostate cancer patients.
Identifiants
pubmed: 31464649
doi: 10.1186/s12955-019-1214-x
pii: 10.1186/s12955-019-1214-x
pmc: PMC6716830
doi:
Types de publication
Journal Article
Validation Study
Langues
eng
Sous-ensembles de citation
IM
Pagination
147Références
Urology. 2000 Dec 20;56(6):899-905
pubmed: 11113727
Spine (Phila Pa 1976). 2000 Dec 15;25(24):3186-91
pubmed: 11124735
J Clin Oncol. 2005 Apr 20;23(12):2772-80
pubmed: 15837992
Nihon Hinyokika Gakkai Zasshi. 2005 Nov;96(7):657-69
pubmed: 16363651
Cancer Nurs. 2007 Nov-Dec;30(6):E19-32
pubmed: 18025909
Psychol Bull. 1979 Mar;86(2):420-8
pubmed: 18839484
Urology. 2010 Nov;76(5):1245-50
pubmed: 20350762
Korean J Urol. 2010 Sep;51(9):601-12
pubmed: 20856644
Prostate Cancer Prostatic Dis. 2012 Jun;15(2):120-7
pubmed: 22212706
Int Braz J Urol. 2013 May-Jun;39(3):344-52
pubmed: 23849583
Qual Life Res. 2014 Oct;23(8):2169-81
pubmed: 24748557
Urologe A. 2015 Nov;54(11):1591-5
pubmed: 26347350
Radiother Oncol. 2016 Jan;118(1):85-91
pubmed: 26780999
Scand J Urol. 2016 Aug;50(4):280-5
pubmed: 27049891
CA Cancer J Clin. 2016 Jul;66(4):271-89
pubmed: 27253694
J Chiropr Med. 2016 Jun;15(2):155-63
pubmed: 27330520
N Engl J Med. 2016 Oct 13;375(15):1425-1437
pubmed: 27626365
Health Qual Life Outcomes. 2016 Dec 6;14(1):168
pubmed: 27923377
JAMA. 2017 Mar 21;317(11):1141-1150
pubmed: 28324092
J Pain Symptom Manage. 2017 Jun;53(6):1085-1090
pubmed: 28438583
Lancet. 1986 Feb 8;1(8476):307-10
pubmed: 2868172
Front Psychol. 2017 Jul 26;8:1215
pubmed: 28798701
Can Urol Assoc J. 2017 Dec;11(12):404-410
pubmed: 29106365
BMC Urol. 2017 Dec 2;17(1):111
pubmed: 29197360
Health Qual Life Outcomes. 2018 Feb 20;16(1):36
pubmed: 29458434
PLoS One. 2019 Apr 4;14(4):e0214682
pubmed: 30946773